Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sandoz
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: HIV Infections|Cytomegalovirus Infections|Cytomegalovirus Retinitis
Phase 1: HIV Infections|Cytomegalovirus Retinitis|Acquired Immunodeficiency Syndrome|Communicable Diseases|Cytomegalovirus Infections|Deficiency Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
071B | P1 |
Completed |
HIV Infections|Cytomegalovirus Retinitis|Cytomegalovirus Infections|Acquired Immunodeficiency Syndrome |
None |
|
MACRT | P2 |
Completed |
HIV Infections|Cytomegalovirus Infections|Cytomegalovirus Retinitis |
None |
|
071A | P1 |
Completed |
Acquired Immunodeficiency Syndrome|Communicable Diseases|HIV Infections|Deficiency Diseases|Cytomegalovirus Infections |
None |